BeyondSpring Inc. (NASDAQ: BYSI) announced its financial results for the quarter ended September 30, 2026, and provided an update on the clinical development of its lead asset, Plinabulin.
The company reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Plinabulin plus docetaxel for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA). This designation applies to patients whose disease has progressed following prior anti-PD-(L)1 therapy and platinum-based chemotherapy. The designation is intended to facilitate more frequent FDA interactions and, if applicable, a rolling review of a future application.
In a strategic transaction completed on September 30, 2026, BeyondSpring sold its wholly owned subsidiary, BeyondSpring Ltd., to Biolin Investment Limited. As consideration, Biolin will fund approximately half of the planned patient enrollment for the global Phase 3 DUBLIN-4 trial. This transaction is expected to support the enrollment of about 221 patients in China, which represents half of the trial's total planned enrollment of 442 patients. BeyondSpring will retain access to clinical data generated from the China portion of the study.
Regarding financial performance, the company reported a net loss of $2.1 million for the quarter ended September 30, 2026, compared to a net loss of $1.6 million for the same period in 2025. Research and development (R&D) expenses increased to $1.1 million for the third quarter of 2026, up from $1.0 million in the prior year, driven by increased preclinical expenses. General and administrative (G&A) expenses rose to $1.0 million in 2026, compared to $0.7 million in 2025, largely due to higher legal fees and consulting expenses.
As of September 30, 2026, the company held $0.6 million in cash, cash equivalents, and short-term investments, a significant decrease from $4.0 million as of December 31, 2025. For the nine months ended September 30, 2026, the company reported a net loss of $5.7 million, with R&D expenses totaling $3.1 million and G&A expenses totaling $2.7 million.
BeyondSpring noted that the DUBLIN-4 trial is designed to evaluate Plinabulin plus docetaxel in the post-immune checkpoint inhibitor setting. The company cited data from the previous DUBLIN-3 trial, published in The Lancet Respiratory Medicine in 2024, which showed a statistically significant improvement in overall survival for non-squamous NSCLC patients treated with Plinabulin plus docetaxel compared to docetaxel alone.
